193 related articles for article (PubMed ID: 28289027)
1. Efficacy of the Investigational Antifungal VT-1161 in Treating Naturally Occurring Coccidioidomycosis in Dogs.
Shubitz LF; Roy ME; Trinh HT; Hoekstra WJ; Schotzinger RJ; Garvey EP
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28289027
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models.
Shubitz LF; Trinh HT; Galgiani JN; Lewis ML; Fothergill AW; Wiederhold NP; Barker BM; Lewis ER; Doyle AL; Hoekstra WJ; Schotzinger RJ; Garvey EP
Antimicrob Agents Chemother; 2015 Dec; 59(12):7249-54. PubMed ID: 26369964
[TBL] [Abstract][Full Text] [Related]
3. The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitis.
Wiederhold NP; Shubitz LF; Najvar LK; Jaramillo R; Olivo M; Catano G; Trinh HT; Yates CM; Schotzinger RJ; Garvey EP; Patterson TF
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437615
[TBL] [Abstract][Full Text] [Related]
4. Selected Clinical Features of Coccidioidomycosis in Dogs.
Davidson AP; Shubitz LF; Alcott CJ; Sykes JE
Med Mycol; 2019 Feb; 57(Supplement_1):S67-S75. PubMed ID: 30690600
[TBL] [Abstract][Full Text] [Related]
5. The novel fungal CYP51 inhibitor VT-1598 displays classic dose-dependent antifungal activity in murine models of invasive aspergillosis.
Garvey EP; Sharp AD; Warn PA; Yates CM; Atari M; Thomas S; Schotzinger RJ
Med Mycol; 2020 Jun; 58(4):505-513. PubMed ID: 32476008
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Nikkomycin Z for respiratory coccidioidomycosis in naturally infected dogs.
Shubitz LF; Roy ME; Nix DE; Galgiani JN
Med Mycol; 2013 Oct; 51(7):747-54. PubMed ID: 23488972
[TBL] [Abstract][Full Text] [Related]
7. The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates
Wiederhold NP; Lockhart SR; Najvar LK; Berkow EL; Jaramillo R; Olivo M; Garvey EP; Yates CM; Schotzinger RJ; Catano G; Patterson TF
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30530603
[No Abstract] [Full Text] [Related]
8. Efficacy of ambruticin analogs in a murine model of coccidioidomycosis.
Shubitz LF; Galgiani JN; Tian ZQ; Zhong Z; Timmermans P; Katz L
Antimicrob Agents Chemother; 2006 Oct; 50(10):3467-9. PubMed ID: 17005834
[TBL] [Abstract][Full Text] [Related]
9. Bicavitary eosinophilic effusion in a dog with coccidioidomycosis.
Piech TL; Jaffey JA; Hostnik ET; White ME
J Vet Intern Med; 2020 Jul; 34(4):1582-1586. PubMed ID: 32447816
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of cutaneous lesions in 23 canine and 17 feline cases of coccidioidomycosis seen in Arizona, USA (2009-2015).
Simões DM; Dial SM; Coyner KS; Schick AE; Lewis TP
Vet Dermatol; 2016 Oct; 27(5):346-e87. PubMed ID: 27397725
[TBL] [Abstract][Full Text] [Related]
11. The dog as a sentinel and animal model for coccidioidomycosis.
Ferguson AJ; Thompson GR; Bruyette D; Sykes JE
Med Mycol; 2024 Jan; 62(1):. PubMed ID: 38148116
[TBL] [Abstract][Full Text] [Related]
12. The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis.
Wiederhold NP; Najvar LK; Jaramillo R; Olivo M; Birch M; Law D; Rex JH; Catano G; Patterson TF
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941638
[TBL] [Abstract][Full Text] [Related]
13. VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model.
Garvey EP; Hoekstra WJ; Moore WR; Schotzinger RJ; Long L; Ghannoum MA
Antimicrob Agents Chemother; 2015 Apr; 59(4):1992-7. PubMed ID: 25605358
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole treatment of refractory coccidioidomycosis in dogs.
Shubitz LF; Schlacks S; Vishkautsan P; Butkiewicz CD; Worthing KA
J Vet Intern Med; 2021 Nov; 35(6):2772-2777. PubMed ID: 34658074
[TBL] [Abstract][Full Text] [Related]
15. Divergence in the approach to tumor necrosis factor α-inhibitor recipients with coccidioidomycosis.
Garrett AL; Cha SS; Wack E; Blair JE
Infection; 2017 Aug; 45(4):539-543. PubMed ID: 28577242
[TBL] [Abstract][Full Text] [Related]
16. Primary cutaneous coccidioidomycosis and subsequent drug eruption to itraconazole in a dog.
Plotnick AN; Boshoven EW; Rosychuk RA
J Am Anim Hosp Assoc; 1997; 33(2):139-43. PubMed ID: 9111724
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis.
Garvey EP; Hoekstra WJ; Schotzinger RJ; Sobel JD; Lilly EA; Fidel PL
Antimicrob Agents Chemother; 2015 Sep; 59(9):5567-73. PubMed ID: 26124165
[TBL] [Abstract][Full Text] [Related]
18. Posaconazole therapy for systemic coccidioidomycosis in a chimpanzee (Pan troglodytes): a case report.
Herrin KV; Miranda A; Loebenberg D
Mycoses; 2005 Nov; 48(6):447-52. PubMed ID: 16262885
[TBL] [Abstract][Full Text] [Related]
19. Experimental animal models of coccidioidomycosis.
Clemons KV; Capilla J; Stevens DA
Ann N Y Acad Sci; 2007 Sep; 1111():208-24. PubMed ID: 17344524
[TBL] [Abstract][Full Text] [Related]
20. Coccidiomycosis in a dog.
Rubensohn M; Stack S
Can Vet J; 2003 Feb; 44(2):159-60. PubMed ID: 12650050
[No Abstract] [Full Text] [Related]
[Next] [New Search]
